Antide - CAS 112568-12-4
Catalog number: B0084-081796
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C82H108ClN17O14
Molecular Weight:
1591.321
COA:
Inquire
Targets:
GNRH Receptor
Description:
Antide is a GnRH and LH-RH antagonist that displays potent anti-ovulatory and weak histamine release activity.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-081796 5 mg $288 In stock
Bulk Inquiry
Brife Description:
GnRH and LH-RH antagonist
Synonyms:
Iturelix; Nal-Lys-GnRH
MSDS:
Inquire
InChIKey:
QRYFGTULTGLGHU-NBERXCRTSA-N
InChI:
InChI=1S/C82H108ClN17O14/c1-50(2)41-65(76(108)95-64(26-11-12-37-88-51(3)4)82(114)100-40-18-27-70(100)81(113)91-52(5)71(84)103)96-75(107)63(25-10-14-39-90-73(105)60-23-17-36-87-48-60)93-74(106)62(24-9-13-38-89-72(104)59-22-16-35-86-47-59)94-80(112)69(49-101)99-79(111)68(45-56-19-15-34-85-46-56)98-78(110)67(43-54-29-32-61(83)33-30-54)97-77(109)66(92-53(6)102)44-55-28-31-57-20-7-8-21-58(57)42-55/h7-8,15-17,19-23,28-36,42,46-48,50-52,62-70,88,101H,9-14,18,24-27,37-41,43-45,49H2,1-6H3,(H2,84,103)(H,89,104)(H,90,105)(H,91,113)(H,92,102)(H,93,106)(H,94,112)(H,95,108)(H,96,107)(H,97,109)(H,98,110)(H,99,111)/t52-,62+,63-,64+,65+,66-,67-,68-,69+,70+/m1/s1
Canonical SMILES:
CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)C2=CN=CC=C2)NC(=O)C(CCCCNC(=O)C3=CN=CC=C3)NC(=O)C(CO)NC(=O)C(CC4=CN=CC=C4)NC(=O)C(CC5=CC=C(C=C5)Cl)NC(=O)C(CC6=CC7=CC=CC=C7C=C6)NC(=O)C
1.GnRH mediates estrous behavior induced by ring A reduced progestins and vaginocervical stimulation.
Gómora-Arrati P1, Beyer C, Lima-Hernández FJ, Gracia ME, Etgen AM, González-Flores O. Behav Brain Res. 2008 Feb 11;187(1):1-8. Epub 2007 Aug 22.
The present study was designed to assess the participation of gonadotropin-releasing hormone (GnRH) in the display of estrous behavior induced by application of vaginal-cervical stimulation (VCS) and by the intracerebroventricular (icv) administration of progesterone and its ring A-reduced metabolites to ovariectomized (ovx), estradiol benzoate (E2B) primed rats. Icv injection of Antide, a GnRH-1 receptor antagonist, significantly depressed lordosis behavior in ovx, E2B-primed rats treated with icv GnRH. Application of VCS to ovx, E2B-primed rats facilitated both lordosis and proceptivity. These behavioral responses were significantly depressed by the icv administration of Antide. Similarly, icv Antide blocked the stimulatory effect on both lordosis and proceptive behaviors elicited by progesterone and its ring A-reduced metabolites: 5alpha-pregnandione (5alpha-DHP), 5alpha-pregnan-3alpha-ol-20-one (5alpha,3alpha-Pgl) and 5beta-pregnan-3beta-hydroxy-20-one (5beta,3beta-Pgl) in ovx, E2B-primed rats.
2.Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs.
Parborell F1, Irusta G, Rodríguez Celín A, Tesone M. Mol Reprod Dev. 2008 Apr;75(4):623-31.
An adequate vascular supply is important to provide endocrine and paracrine signals during follicular development. We evaluated the direct in vivo effects of both the GnRH-agonist Leuprolide acetate (LA) and the GnRH-antagonist Antide (Ant) on the expression of VEGF-A and ANPT-1 and their receptors in ovarian follicles from prepubertal eCG-treated rats. We also examined whether the changes observed in apoptosis by GnRH-I analogs have an effect on the caspase cascade. LA significantly decreased the levels of VEGF-A, its receptor Flk-1, and ANPT-1 when compared to controls, while the co-injection of Ant interfered with this effect. No changes were observed in the levels of Tie-2 after treatment with these analogs. When we measured the follicular content of caspase-3 protein, we observed that LA significantly increased the level of the active form. The co-injection of Ant interfered with this effect and Ant alone significantly decreased caspase-3 cleavage.
3.Ubiquitination as a priming process of PKC alpha and PKC epsilon degradation in the alphaT3-1 gonadotrope cell line.
Poulin B1, Maccario H, Thirion S, Junoy B, Boyer B, Enjalbert A, Drouva SV. Neuroendocrinology. 2009;89(3):252-66. doi: 10.1159/000164694. Epub 2008 Oct 16.
BACKGROUND/AIM: Protein kinase C (PKC) is a family of isoenzymes playing a key role in the regulation of gonadotrope cell functions. Specific PKC isoforms are activated and downregulated differentially by gonadotropin-releasing hormone (GnRH) and the phorbol ester TPA. In the present study, focusing mainly on PKC epsilon, the mechanisms underlying the proteasome-dependent downregulation of GnRH-activated PKC epsilon and TPA-sensitive PKC alpha and epsilon isoenzymes were investigated in alphaT3-1 gonadotrope cells.
4.Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway.
Kim KY1, Choi KC, Auersperg N, Leung PC. Endocr Relat Cancer. 2006 Mar;13(1):211-20.
In our previous studies, we demonstrated that ERK1/2 (extracellular signal-regulated protein kinase) and p38 MAPK (mitogen-activated protein kinase) are required for gonadotropin-releasing hormone (GnRH)-II-induced anti-proliferation of ovarian cancer cells. In the present study, we examined the role of the GnRH-I receptor, as well as the activation of protein kinase C (PKC), in the anti-proliferative effect induced by GnRH-I or II in ovarian cancer cells. Our results demonstrated that Antide, a GnRH-I antagonist, reversed the activation of ERK1/2 induced by GnRH-I or II and abolished the anti-proliferative effect of GnRH-I and II in ovarian cancer cells. Transfection of short-interfering RNA to abrogate the gene expression of the GnRH-I receptor reversed GnRH-I and II-induced anti-proliferation. These results indicate that GnRH-I or II induce anti-proliferation through the GnRH-I receptor in ovarian cancer cells. In addition, the activation of ERK1/2 by GnRH-I or II was mimicked by phorbol-12-myristate 13-acetate, a PKC activator.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GNRH Receptor Products


CAS 53714-56-0 Leuprorelin

Leuprorelin
(CAS: 53714-56-0)

Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue used to treat prostate cancer and breast cancer.

CAS 112568-12-4 Antide

Antide
(CAS: 112568-12-4)

Antide is a GnRH and LH-RH antagonist that displays potent anti-ovulatory and weak histamine release activity.

CAS 263847-55-8 AG 045572

AG 045572
(CAS: 263847-55-8)

AG 045572, a nonpeptidic GnRH antagonist, could probably be used in the treatment for sex hormone-dependent diseases and infertility.

CAS 86220-42-0 Nafarelin Acetate Hydrate (1:x:x)

Nafarelin Acetate Hydrate (1:x:x)
(CAS: 86220-42-0)

Nafarelin, under the brand name Synarel, is a gonadotropin-releasing hormone (GnRH) agonist. It can decrease pituitary secretion of the gonadotropins luteinizin...

CAS 78115-72-7 Nafarelin Acetate

Nafarelin Acetate
(CAS: 78115-72-7)

Nafarelin is a GnRH (gonadotropin-releasing hormone) agonist . Its proposed mechanism of action is the desensitization of pituitary gonadotropin-releasing hormo...

CAS 82318-06-7 Deslorelin acetate

Deslorelin acetate
(CAS: 82318-06-7)

Deslorelin acetate is an injectable gonadotropin-releasing hormone (GnRH) super-agonist (also known as an LHRH agonist). It is used in treatment of precocious p...

CAS 52699-48-6 Gonadorelin Acetate Hydrate (1:x:x)

Gonadorelin Acetate Hydrate (1:x:x)
(CAS: 52699-48-6)

Gonadorelin Acetate is a gonadotropin-releasing hormone (GnRH) analog.

CAS 214766-78-6 Degarelix acetate

Degarelix acetate
(CAS: 214766-78-6)

Degarelix acetate is a reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. Degarelix reduces the secretion of luteinizing hormone (LH) and te...

Chemical Structure

CAS 112568-12-4 Antide

Quick Inquiry

Verification code

Featured Items